Denali Therapeutics Inc. (DNLI) Misses Q2 EPS by 4c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of ($0.68), $0.04 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $11.94 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Bessent: We Make A Market Buying Older Bonds
• Increasing unusual put volume: MNDY BILI HWM SHW NVS AEP GRAB AXTX STT CAMT XEL TRIP ROST BCRX SBLK
• US consumers’ inflation outlook steady in August, Fed report shows